TherapeuticsMD, Inc. (NASDAQ: TXMD)
TherapeuticsMD, Inc. (TXMD), a women’s health care company, yesterday announced positive top line results from their Phase 3 Rejoice Trial of TX-004HR. TX-004HR is used for the treatment of postmenopausal women who suffer from vulvar and vaginal atrophy. The study’s results showed that TX-004HR had statistical improvement over the placebo.
TherapeuticsMD, Inc. CEO Comments
“We are extremely encouraged that all three doses of TX-004HR studied in the Rejoice Trial demonstrated positive results,” said TherapeuticsMD CEO Robert G. Finizio. “With efficacy observed as early as two weeks and the convenience of the applicator-free vaginal softgel, we believe that, if approved, TX-004HR has the potential to offer a highly differentiated, new treatment option that meets the needs of the millions of postmenopausal women with VVA who are suffering from pain during sexual intercourse. We look forward to sharing the Rejoice Trial results and to submitting a New Drug Application for TX-004HR to the Food and Drug Administration as soon as the first half of 2016.” Business Wire
TXMD Technical Analysis
TXMD gapped up in price yesterday to $8.57, up from the prior day’s close of $6.53, which is a 31% increase on the favorable news. Taking a look at the daily chart, we can see the last time TXMD traded at this price level was on July 24th, when it traded at highs of $8.75. Taking a closer look at the daily chart, we can see that TXMD is approaching its 52 week high price of $8.83 reached on July 23rd. Usually, when a stock breaks its 52 week high price it will shoot right through it for a big move. That is exactly the move I will be anticipating for TXMD. TXMD has a float of 134.1 million shares and was trading over 10 times the normal daily trading volume. TXMD did reach pre market highs of $10.08, but gave back $1.51 at the open, or equivalent to 23%. For trading purposes, my entry point would have been $8.65 looking for a run through $9. My stop loss would have been $8.50, fearing anything below that and the stock would start to fill in the gap up.
TherapeuticsMD, Inc. operates as a womens health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company also focuses on conducting the clinical trials for hormone therapy pharmaceutical products that are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. In addition, it manufactures and distributes branded and generic prescription prenatal, as well as OTC vitamins. TherapeuticsMD markets its products primarily through a direct national sales force to health care providers, as well as directly through its Website. The company was founded in 2008 and is headquartered in Boca Raton, Florida. Yahoo Finance